Abstract
This study describes the development and regression of crizotinib-associated complex renal cysts (CACRCs) in a female patient with ALK-positive advanced non-small cell lung cancer with an ongoing complete response while on continuous crizotinib treatment. The clinical context of crizotinib use requires frequent imaging studies; therefore observation is probably the best approach to CACRC management in asymptomatic patients. The natural history of CACRCs remains unknown, and large-scale longitudinal follow-up studies of these cysts are eagerly awaited.
MeSH terms
-
Carcinoma, Non-Small-Cell Lung / complications
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Crizotinib
-
Cysts / chemically induced
-
Cysts / pathology*
-
Female
-
Humans
-
Kidney / drug effects
-
Kidney / pathology
-
Kidney Diseases, Cystic / chemically induced
-
Kidney Diseases, Cystic / diagnosis
-
Kidney Diseases, Cystic / pathology*
-
Middle Aged
-
Pyrazoles / administration & dosage
-
Pyrazoles / adverse effects*
-
Pyridines / administration & dosage
-
Pyridines / adverse effects*
Substances
-
Pyrazoles
-
Pyridines
-
Crizotinib